Yong Tai

Yongtai Biopharm is a leading Chinese biotechnology company focused on the development and commercialization of cellular immunotherapy products. The company's core product, EAL, is an autologous activated lymphocyte therapy and represents the first cellular immunotherapy to enter a Phase 2/3 clinical trial in China for the prevention of postsurgical recurrence of liver cancer. Beyond EAL, Yongtai Biopharm maintains a robust pipeline of CAR-T and TCR-T cell therapies targeting various hematological and solid tumors, including B-cell acute lymphoblastic leukemia and ovarian cancer. The company operates integrated research, development, and GMP-compliant manufacturing facilities to support its clinical programs. Yongtai Biopharm is listed on the Hong Kong Stock Exchange and is a pioneer in the rapidly evolving cell therapy landscape in East Asia.